Therapy Areas: Oncology
Harpoon Therapeutics completes USD70m series C equity financing
13 November 2018 -

Harpoon Therapeutics, a clinical-stage immunotherapy company engaged in the development of a class of T cell engagers, has completed a USD70m series C equity financing, it was reported yesterday.

The lead new investor is OrbiMed, along with new investors Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures and NS Investment. The company's present investors, MPM Capital, Oncology Impact Fund, Arix Bioscience, New Leaf Venture Partners and Taiho Ventures also participated in the Series C financing round.

The company aims to use the proceeds from the financing to support further advancement of its immunotherapy programs based on its TriTAC (Tri-specific T cell Activating Construct) and ProTriTAC (Protease-activated Tri-specific T Cell Activating Construct) platforms, which are designed to harness the natural power of the body's immune system to fight cancer and other diseases. The company's TriTAC platform was designed to advance the therapeutic potential of T cell engagers, with a long half-life extended format.

Login
Username:

Password: